Page last updated: 2024-10-22

aminoglutethimide and Local Neoplasm Recurrence

aminoglutethimide has been researched along with Local Neoplasm Recurrence in 27 studies

Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.

Research Excerpts

ExcerptRelevanceReference
"To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer."9.10Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003)
"Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years."9.09Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001)
"In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared."9.06Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989)
"About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs."7.67Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984)
"This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer."7.67Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987)
"In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation."7.67Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986)
"Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day."7.66Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982)
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."6.36Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977)
"To determine whether the addition of aminoglutethimide to tamoxifen is able to improve the outcome in postmenopausal patients with hormone receptor-positive, early-stage breast cancer."5.10Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. ( Fridrik, M; Gnant, M; Haider, K; Hausmaninger, H; Jakesz, R; Kubista, E; Kwasny, W; Menzel, C; Mlineritsch, B; Samonigg, H; Schmid, M; Seifert, M; Steger, G; Steindorfer, P; Stierer, M; Taucher, S; Tausch, C; Wette, V, 2003)
"Three hundred eighty postmenopausal breast cancer patients receiving adjuvant tamoxifen treatment for 3 years were randomized to either continue tamoxifen for 2 more years or to switch to low-dose aminoglutethimide (250 mg daily) for 2 years."5.09Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. ( Amoroso, D; Boccardo, F; Caroti, C; Cruciani, G; Farris, A; Mesiti, M; Mustacchi, G; Romeo, D; Rubagotti, A; Schieppati, G; Villa, E, 2001)
"In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63."5.07[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994)
"In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared."5.06Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989)
"About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs."3.67Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984)
"This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer."3.67Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987)
"In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation."3.67Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986)
"Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day."3.66Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982)
"The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases."2.39Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995)
" There is a tendency towards an increased response-rate with increased dosage of progestin, in both endometrial and breast carcinoma, while the route of administration appears to be of minor importance."2.37Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. ( Kauppila, A, 1984)
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."2.36Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977)
"Tamoxifen was tried in three patients after relapse following adrenalectomy; all three patients responded with a mean duration of 9 months."1.27Metastatic breast cancer in males. Assessment of endocrine therapy. ( Dao, TL; Nemoto, T; Patel, JK, 1984)
"14 males with disseminated cancer of breast received a total of 35 endocrine trials, mainly in the form of hormonal supplementation."1.27Hormonal treatment of disseminated male breast cancer. ( Di Lauro, L; Lazzaro, B; Lopez, M; Papaldo, P, 1985)
"42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis."1.26Aminoglutethimide in treatment of metastatic breast carcinoma. ( Fahmy, DR; Fitzharris, BM; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Neville, AM; Powles, TJ; Smith, IE, 1978)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-199021 (77.78)18.7374
1990's4 (14.81)18.2507
2000's2 (7.41)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schmid, M1
Jakesz, R1
Samonigg, H1
Kubista, E1
Gnant, M1
Menzel, C1
Seifert, M1
Haider, K1
Taucher, S1
Mlineritsch, B1
Steindorfer, P1
Kwasny, W1
Stierer, M1
Tausch, C1
Fridrik, M1
Wette, V1
Steger, G1
Hausmaninger, H1
Kaye, SB1
Woods, RL1
Fox, RM1
Coates, AS1
Tattersall, MH1
Patel, JK1
Nemoto, T1
Dao, TL1
Dowsett, M2
Harris, AL3
Smith, IE2
Jeffcoate, SL1
Kauppila, A1
Taylor, RE1
Powles, TJ2
Humphreys, J1
Bettelheim, R1
Casey, AJ1
Neville, AM2
Coombes, RC1
Wells, SA2
Worgul, TJ1
Samojlik, E2
Boucher, AE1
Lipton, A2
Harvey, H2
White, D1
Smart, E1
Cox, C1
Santen, RJ2
Ingle, JN1
Green, SJ1
Ahmann, DL1
Edmonson, JH1
Nichols, WC1
Frytak, S1
Rubin, J1
Costanza, ME1
Scher, HI2
Steineck, G1
Kelly, WK2
Garcia-Giralt, E1
Omodei Zorini, C1
Ferri, L1
Ayme, Y1
Carton, M1
Daban, A1
Delozier, T1
Fargeot, P1
Fumoleau, P1
Gorins, A1
Zhang, ZF1
Nanus, D1
Boccardo, F1
Rubagotti, A1
Amoroso, D1
Mesiti, M1
Romeo, D1
Caroti, C1
Farris, A1
Cruciani, G1
Villa, E1
Schieppati, G1
Mustacchi, G1
Fitzharris, BM1
McKinna, JA1
Fahmy, DR1
Nash, AG1
Gazet, JC1
Ford, HT1
Ruby, EB1
Kendall, J1
Seymour, L1
Bezwoda, WR1
Meyer, K1
Nicholson, S2
Sainsbury, JR2
Halcrow, P2
Chambers, P2
Farndon, JR2
Lundgren, S1
Gundersen, S1
Klepp, R1
Lønning, PE1
Lund, E1
Kvinnsland, S1
Labrie, F1
Dupont, A1
Bélanger, A1
Cusan, L1
Brochu, M1
Turina, E1
Pinault, S1
Lacourciere, Y1
Emond, J1
Andersen, J1
Poulsen, HS1
Lopez, M1
Di Lauro, L1
Lazzaro, B1
Papaldo, P1
Grem, JL1
Falkson, G1
Love, RR1
Tormey, DC2
Angus, B1
Horton, J1
Knuiman, M1
Keller, AM1
Vogel, H1
Gale, KE1
Hahn, RG1
Rosenbluth, RJ1
Höffken, K1
Kempf, H1
Miller, AA1
Miller, B1
Schmidt, CG1
Faber, P1
Kley, HK1
Paterson, AH1
Howell, A1
Ribeiro, G1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients[NCT00309491]Phase 32,021 participants (Actual)Interventional1990-12-31Completed
A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormon[NCT02730923]Phase 1/Phase 272 participants (Anticipated)Interventional2016-04-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for aminoglutethimide and Local Neoplasm Recurrence

ArticleYear
Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations.
    Acta obstetricia et gynecologica Scandinavica, 1984, Volume: 63, Issue:5

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bromocriptine;

1984
Hormone-refractory (D3) prostate cancer: refining the concept.
    Urology, 1995, Volume: 46, Issue:2

    Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu

1995
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
    Urology, 1996, Volume: 47, Issue:1A Suppl

    Topics: Aminoglutethimide; Androgen Antagonists; Clinical Trials as Topic; Flutamide; Humans; Male; Neoplasm

1996
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Cancer, 1977, Volume: 39, Issue:6 Suppl

    Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy

1977

Trials

6 trials available for aminoglutethimide and Local Neoplasm Recurrence

ArticleYear
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Proto

2003
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
    Cancer research, 1982, Volume: 42, Issue:8 Suppl

    Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Hydroc

1982
Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
    Cancer research, 1982, Volume: 42, Issue:8 Suppl

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combinatio

1982
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
    La Clinica terapeutica, 1994, Volume: 145, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans

1994
Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-15, Volume: 19, Issue:22

    Topics: Aged; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Resista

2001
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
    Breast cancer research and treatment, 1989, Volume: 14, Issue:2

    Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Megest

1989

Other Studies

17 other studies available for aminoglutethimide and Local Neoplasm Recurrence

ArticleYear
Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
    Cancer research, 1982, Volume: 42, Issue:8 Suppl

    Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause

1982
Metastatic breast cancer in males. Assessment of endocrine therapy.
    Cancer, 1984, Mar-15, Volume: 53, Issue:6

    Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Humans; Male; Middle Ag

1984
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    The Journal of clinical endocrinology and metabolism, 1984, Volume: 58, Issue:1

    Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Fe

1984
Effects of endocrine therapy on steroid-receptor content of breast cancer.
    British journal of cancer, 1982, Volume: 45, Issue:1

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Estrogen Antagonists; Estrogens, Conju

1982
The medical management of breast cancer.
    Clinical obstetrics and gynecology, 1982, Volume: 25, Issue:2

    Topics: Adjuvants, Pharmaceutic; Adult; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castrati

1982
Aminoglutethimide in treatment of metastatic breast carcinoma.
    Lancet (London, England), 1978, Sep-23, Volume: 2, Issue:8091

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neopl

1978
Response to second-line hormone treatment for advanced breast cancer. Predictive value of ploidy determination.
    Cancer, 1990, Jun-15, Volume: 65, Issue:12

    Topics: Aminoglutethimide; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dip

1990
Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
    Lancet (London, England), 1989, Jan-28, Volume: 1, Issue:8631

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; ErbB Receptors; Fema

1989
Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
    British journal of urology, 1989, Volume: 63, Issue:6

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flutam

1989
Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer.
    Cancer, 1989, Nov-01, Volume: 64, Issue:9

    Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diethylst

1989
Hormonal treatment of disseminated male breast cancer.
    Oncology, 1985, Volume: 42, Issue:6

    Topics: Adult; Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Breast Neoplasms; Castration;

1985
A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
    American journal of clinical oncology, 1988, Volume: 11, Issue:5

    Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr

1988
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
    British journal of cancer, 1988, Volume: 58, Issue:6

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; ErbB Receptors; Female; Humans; Hydroc

1988
Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
    Cancer, 1987, Nov-01, Volume: 60, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B

1987
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
    Cancer treatment reports, 1986, Volume: 70, Issue:10

    Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Female; Hormones;

1986
Chemotherapy and hormone therapy of metastatic breast cancer.
    The Southeast Asian journal of tropical medicine and public health, 1985, Volume: 16, Issue:4

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali

1985
Management of advanced carcinoma of the breast.
    The Practitioner, 1985, Volume: 229, Issue:1401

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali

1985